Scotiabank Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock

Key Points

• Scotiabank raised AbbVie’s price target to $320 from $280 and maintained a “sector outperform” rating, implying roughly 20.3% upside from the prior close. Analysts overall rate the stock “Moderate Buy,” with an average target of $273.82.
• AbbVie reported quarterly EPS of $3.65, exceeding estimates, while revenue rose 10.2% year over year to $16.99 billion. The stock opened at $265.93 and is trading near its 52-week high.
• Recent pipeline developments support growth prospects, including positive Phase 3 lymphoma results for epcoritamab with Genmab and FDA approval of a new Parkinson’s treatment, though the company also lowered its 2026 adjusted EPS guidance after acquisition-related expenses.

AbbVie (NYSE:ABBV - Get Free Report) had its target price raised by Scotiabank from $280.00 to $320.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a "sector outperform" rating on the stock. Scotiabank's target price would suggest a potential upside of 20.33% from the company's previous close.

Several other research analysts also recently issued reports on the stock. UBS Group boosted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Monday, July 13th. Guggenheim upped their target price on AbbVie from $261.00 to $288.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. BNP Paribas Exane increased their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. Finally, Citigroup raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average target price of $273.82.

AbbVie Trading Up 1.2%

NYSE ABBV opened at $265.93 on Tuesday. AbbVie has a 1 year low of $190.75 and a 1 year high of $269.39. The company has a fifty day simple moving average of $258.05 and a 200 day simple moving average of $235.01. The company has a market cap of $469.84 billion, a P/E ratio of 75.12, a P/E/G ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The business's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts forecast that AbbVie will post 14.05 EPS for the current fiscal year.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Institutional Trading of AbbVie

Hedge funds have recently bought and sold shares of the stock. Tompkins Financial Corp raised its holdings in shares of AbbVie by 0.4% during the third quarter. Tompkins Financial Corp now owns 35,524 shares of the company's stock worth $9,293,000 after acquiring an additional 156 shares during the period. Adelphi Trust Co grew its holdings in shares of AbbVie by 1.9% in the 3rd quarter. Adelphi Trust Co now owns 10,668 shares of the company's stock valued at $2,791,000 after acquiring an additional 204 shares in the last quarter. Heartwood Wealth Advisors LLC increased its position in shares of AbbVie by 6.5% during the 3rd quarter. Heartwood Wealth Advisors LLC now owns 1,116 shares of the company's stock worth $292,000 after purchasing an additional 68 shares during the last quarter. Miller Global Investments LLC increased its holdings in AbbVie by 582.5% during the third quarter. Miller Global Investments LLC now owns 389 shares of the company's stock worth $102,000 after buying an additional 332 shares during the last quarter. Finally, Polaris Financial Partners acquired a new position in shares of AbbVie during the 3rd quarter worth about $205,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and partner Genmab reported positive Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The treatment produced a statistically significant and clinically meaningful improvement in progression-free survival versus R-CHOP alone, potentially expanding epcoritamab into frontline treatment and supporting future regulatory filings. AbbVie and Genmab lymphoma trial announcement
• Positive Sentiment: The lymphoma result strengthens AbbVie’s bispecific-antibody strategy and could add a new growth opportunity as the company seeks to diversify beyond its mature immunology portfolio. Reports indicated the combination reduced the risk of progression or death by approximately 51%. AbbVie lymphoma trial risk reduction report
• Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s treatment, described as the first approved selective D1/D5 drug, adding another commercial product to the company’s neuroscience franchise. AbbVie Parkinson’s treatment approval
• Neutral Sentiment: AbbVie joined a federal 340B rebate pilot program ahead of its planned 2027 launch. The impact is uncertain, but the program could influence future pricing and reimbursement for participating medicines. AbbVie 340B rebate pilot
• Negative Sentiment: AbbVie lowered third-quarter 2026 adjusted EPS guidance to $3.73–$3.77, below the approximately $3.85 analyst consensus, after including $216 million of acquired in-process research and development and milestone expenses. Full-year adjusted EPS guidance was reduced to $13.76–$13.96 from $13.87–$14.07. AbbVie updated earnings guidance

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.